BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37814378)

  • 1. Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development.
    Tomlinson L; Ramsden D; Leite SB; Beken S; Bonzo JA; Brown P; Candarlioglu PL; Chan TS; Chen E; Choi CK; David R; Delrue N; Devine PJ; Ford K; Garcia MI; Gosset JR; Hewitt P; Homan K; Irrechukwu O; Kopec AK; Liras JL; Mandlekar S; Raczynski A; Sadrieh N; Sakatis MZ; Siegel J; Sung K; Sunyovszki I; Van Vleet TR; Ekert JE; Hardwick RN
    Adv Biol (Weinh); 2023 Oct; ():e2300131. PubMed ID: 37814378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate).
    Baran SW; Brown PC; Baudy AR; Fitzpatrick SC; Frantz C; Fullerton A; Gan J; Hardwick RN; Hillgren KM; Kopec AK; Liras JL; Mendrick DL; Nagao R; Proctor WR; Ramsden D; Ribeiro AJS; Stresser D; Sung KE; Sura R; Tetsuka K; Tomlinson L; Van Vleet T; Wagoner MP; Wang Q; Arslan SY; Yoder G; Ekert JE
    ALTEX; 2022; 39(2):297–314. PubMed ID: 35064273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary.
    Baker TK; Van Vleet TR; Mahalingaiah PK; Grandhi TSP; Evers R; Ekert J; Gosset JR; Chacko SA; Kopec AK
    Drug Metab Dispos; 2024 Feb; 52(3):198-209. PubMed ID: 38123948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications.
    Fabre K; Berridge B; Proctor WR; Ralston S; Will Y; Baran SW; Yoder G; Van Vleet TR
    Lab Chip; 2020 Mar; 20(6):1049-1057. PubMed ID: 32073020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
    Tan DCT; Khong YM; Mount S; Galella E; Mitra B; Charlton S; Kuhli M; Ternik R; Walsh J; Rajapakshe A; Thompson K; Mehrotra S; Santangelo M; Liu J; Dixit T; Schaufelberger D; Jamzad S; Klein S; Hoag SW; Wang J; Fletcher EP; Khurana M; Alexander J; Radden E; Sood R; Selen A
    Eur J Pharm Biopharm; 2021 Jul; 164():54-65. PubMed ID: 33878432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development.
    Marx U; Akabane T; Andersson TB; Baker E; Beilmann M; Beken S; Brendler-Schwaab S; Cirit M; David R; Dehne EM; Durieux I; Ewart L; Fitzpatrick SC; Frey O; Fuchs F; Griffith LG; Hamilton GA; Hartung T; Hoeng J; Hogberg H; Hughes DJ; Ingber DE; Iskandar A; Kanamori T; Kojima H; Kuehnl J; Leist M; Li B; Loskill P; Mendrick DL; Neumann T; Pallocca G; Rusyn I; Smirnova L; Steger-Hartmann T; Tagle DA; Tonevitsky A; Tsyb S; Trapecar M; Van de Water B; Van den Eijnden-van Raaij J; Vulto P; Watanabe K; Wolf A; Zhou X; Roth A
    ALTEX; 2020; 37(3):365-394. PubMed ID: 32113184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Toward Regulatory Acceptance of MPS-Cardiac Safety Assessment as an Example].
    Yamazaki D
    Yakugaku Zasshi; 2023; 143(1):55-63. PubMed ID: 36596540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of microphysiological systems for nonclinical evaluation of cell therapies.
    Candarlioglu P; Delsing L; Gauthier L; Lewis L; Papadopoulos G; Freag M; Chan TS; Homan K; Fellows MD; Pointon A; Kojala K
    ALTEX; 2024 May; ():. PubMed ID: 38746991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research and Development of Microphysiological Systems in Japan Supported by the AMED-MPS Project.
    Ishida S
    Front Toxicol; 2021; 3():657765. PubMed ID: 35295097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microphysiological systems in early stage drug development: Perspectives on current applications and future impact.
    Kopec AK; Yokokawa R; Khan N; Horii I; Finley JE; Bono CP; Donovan C; Roy J; Harney J; Burdick AD; Jessen B; Lu S; Collinge M; Sadeghian RB; Derzi M; Tomlinson L; Burkhardt JE
    J Toxicol Sci; 2021; 46(3):99-114. PubMed ID: 33642521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technical aspects of microphysiological systems (MPS) as a promising wet human-in-vivo simulator.
    Kanamori T; Sugiura S; Sakai Y
    Drug Metab Pharmacokinet; 2018 Feb; 33(1):40-42. PubMed ID: 29217459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status of MPS research toward social implementation].
    Sakai Y; Kimura H
    Nihon Yakurigaku Zasshi; 2022; 157(5):330-334. PubMed ID: 36047147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective.
    Ainslie GR; Davis M; Ewart L; Lieberman LA; Rowlands DJ; Thorley AJ; Yoder G; Ryan AM
    Lab Chip; 2019 Sep; 19(19):3152-3161. PubMed ID: 31469131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development.
    Hargrove-Grimes P; Low LA; Tagle DA
    Cells Tissues Organs; 2022; 211(3):269-281. PubMed ID: 34380142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives.
    Marshall S; Madabushi R; Manolis E; Krudys K; Staab A; Dykstra K; Visser SAG
    CPT Pharmacometrics Syst Pharmacol; 2019 Feb; 8(2):87-96. PubMed ID: 30411538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology.
    Watson DE; Hunziker R; Wikswo JP
    Exp Biol Med (Maywood); 2017 Oct; 242(16):1559-1572. PubMed ID: 29065799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microphysiological systems as reliable drug discovery and evaluation tools: Evolution from innovation to maturity.
    Moon HR; Surianarayanan N; Singh T; Han B
    Biomicrofluidics; 2023 Dec; 17(6):061504. PubMed ID: 38162229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies.
    Phillips JA; Grandhi TSP; Davis M; Gautier JC; Hariparsad N; Keller D; Sura R; Van Vleet TR
    Lab Chip; 2020 Feb; 20(3):468-476. PubMed ID: 31989145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerating Global Deletion of the Abnormal Toxicity Test for vaccines and biologicals. Planning common next steps. A workshop Report.
    Viviani L; Reid K; Gastineau T; Milne C; Smith D; Levis R; Lei D; van Ooij M; Gilbert PA; Vandeputte J; Xie J; Madhuri L; Shaid S; Kubiak V; Suri R; Mizukami T; Shirasaki Y; Li X; Zhou YY; Trapkova A; Goel S; Prakash J; Subagio AA; Suwarni E; Jung KJ; Sanyal G; Das P; Coppens E; Wright D; Peng Z; Northeved H; Jungbäck C; Kirpitchenok T; Del Pace L; Seo B; Poojary B; Ottoni A
    Biologicals; 2022 Jul; 78():17-26. PubMed ID: 35840492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.